Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

L-907

Supelco

Lormetazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H12Cl2N2O2
CAS Number:
848-75-9
Molecular Weight:
335.18
EC Number:
200-659-6
MDL number:
MFCD00058578
UNSPSC Code:
41116107
PubChem Substance ID:
329817667
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CN1C(=O)C(O)N=C(c2ccccc2Cl)c3cc(Cl)ccc13

InChI

1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3

InChI key

FJIKWRGCXUCUIG-UHFFFAOYSA-N

General description

Lormetazepam is a benzodiazepine with sedative-hypnotic, anxiolytic, anticonvulsant, and muscle relaxant effects. This certified solution standard is suitable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Lormetazepam is sold under trade names Loramet and Noctamid for treatment of insomnia.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hervé Allain et al.
European journal of clinical pharmacology, 59(3), 179-188 (2003-05-21)
In elderly patients, both falls and impaired memory are considerable medical problems. Hypnotics, which are frequently administered to this patient group for the treatment of insomnia, should ideally not impair equilibrium or memory functions. This double-blind, randomised, four-way, cross-over study
Francesco Benedetti et al.
International clinical psychopharmacology, 19(5), 311-317 (2004-08-04)
Benzodiazepines can shift the phase of circadian rhythms in mammalian species, but few data are available on their phase-response effects in humans, and on possible links between timing of administration and hypnotic efficacy. Using a placebo-controlled, cross-over design, we evaluated
Inga Katofsky et al.
Sleep medicine, 13(5), 463-468 (2012-02-22)
This study was conducted to evaluate the effectiveness of a cognitive behavioral self-help program (SHP) in combination with pharmacotherapy in patients with primary insomnia in general practice. Patients were recruited from 31 general practitioners (GPs) in the Hamburg area, who
E Nováková
Soudni lekarstvi, 43(1), 2-4 (1998-04-30)
The determination of benzodiazepine derivatives lorazepam and lormetazepam in urine is based on detection of their metabolites 2-amino-2',5-dichlorobenzophenone and 2-methylamino-2'5-dichlorbenzophenone in hydrolyzed urine. Both substances are structurally very similar to the metabolites of diazepam 2-amino-5-chlorbenzophenone and 2-methylamino-5-chlorbenzophenone and their mobility
D Riemann et al.
Pharmacopsychiatry, 35(5), 165-174 (2002-09-19)
In recent years, sedating antidepressants have been increasingly used to treat primary insomnia. Up to now, only one open pilot study with trimipramine and one double-blind placebo-controlled study with doxepin have provided scientific support for this approach in treating primary
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service